LATEST NEWS

---

September 3, 2025: ‘Radiance Biopharma signs exclusive license For ‘First In Class’ c-Met/EGFR targeted Nano Antibody ADC‘ – GlobeNewswire

More……

September 2, 2025: ‘Boston biotech Radiance offers China firm $1B-plus for rights to next-gen ADC‘ – FIERCE Biotech

More……

---

Radiance Biopharma’s mission is to develop a pipeline of next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer and other high unmet medical needs.

---

Radiance’s Board of Directors, Management and Advisors are industry veterans with experience in both large pharma and biotechnology startups and are committed to transforming the lives of patients with cancer.

---

RB-601 is a ‘First-in-Man’ Nano Antibody Drug Conjugate targeting tumors expressing c-MET and EGFR. Learn more

---

RB-203 is a proprietary monoclonal antibody recognizing membrane Hsp70 which is expressed on the majority of tumors, but not normal cells. Learn more